Pax1 and Pax9 activate Bapx1 to induce chondrogenic differentiation in the sclerotome. by Rodrigo, Isabel et al.
INTRODUCTION
The axial skeleton of vertebrate organisms originates from
somites, which are paraxial mesoderm structures that lie on
either side of the neural tube and the notochord. Soon after
their formation, the epithelial somites start to differentiate in
response to signals from surrounding tissues. The ventromedial
region of the somites de-epithelializes to form the
mesenchymal sclerotome, whereas the dorsolateral part
remains epithelial and forms the dermomyotome. Sclerotomal
cells migrate towards the notochord where they condense to
form mesenchymal prevertebrae. Sclerotomal cells located
around the notochord contribute to the vertebral bodies and
intervertebral discs of the future vertebral column. The lateral
sclerotome participates in the formation of the ribs and
neural arches. After forming mesenchymal condensations,
sclerotomal cells differentiate into chondroblasts to form the
cartilagous anlagen of the vertebral column, which is
subsequently replaced by bony tissues through endochondral
ossification (Brand-Saberi and Christ, 2000).
Pax1 and Pax9 play a critical role in the formation of the
axial skeleton. They belong to the Pax family of transcription
factors, characterized by the presence of a conserved DNA
binding domain: the paired box. Pax genes were originally
identified in Drosophila, but later they have been found in
numerous organisms where they play important roles in
embryonic patterning and organogenesis. Among them, Pax1
and Pax9 constitute a paralogous group characterized by the
presence of the paired-box and the octapeptide domain, and the
absence of a homeobox (Strachan and Read, 1994).
Pax1 and Pax9 show a similar but not identical expression
pattern during mouse development. They are expressed in
the developing sclerotome, where no other Pax genes are
expressed. Pax1 is first expressed in nascent somites shortly
before de-epithelialization, by cells located in the ventromedial
part, which marks the emerging sclerotome population. Pax1
is initially expressed in all sclerotomal cells, but later its
expression becomes stronger in the posterior ventromedial
compartment. Subsequently, Pax9 is expressed in the posterior
ventrolateral compartment of the sclerotome. Thus, Pax1 is
predominantly expressed in the region of the future vertebral
bodies and intervertebral discs, whereas the Pax9 expression
domain extends more laterally in the region of the future neural
arches and the proximal part of the ribs (Deutsch et al., 1988;
Neubüser et al., 1995).
Pax1 is required for the proper formation of ventral
structures of the vertebral column (Balling et al., 1988; Wallin
et al., 1994; Wilm et al., 1998). Although Pax9-deficient
mutant mice have no apparent malformations in the axial
skeleton (Peters et al., 1998), Pax1;Pax9-double mutants show
a dramatic increase in the severity of the vertebral defects when
compared with Pax1-deficient mutants. In the absence of both
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We have previously shown that the paired-box
transcription factors Pax1 and Pax9 synergistically act in
the proper formation of the vertebral column. Nevertheless,
downstream events of the Pax1/Pax9 action and their target
genes remain to be elucidated. We show, by analyzing
Pax1;Pax9 double mutant mice, that expression of Bapx1
in the sclerotome requires the presence of Pax1 and Pax9,
in a gene dose-dependent manner. By using a retroviral
system to overexpress Pax1 in chick presomitic mesoderm
explants, we show that Pax1 can substitute for Shh in
inducing Bapx1 expression and in initiating chondrogenic
differentiation. Furthermore, we demonstrate that Pax1
and Pax9 can transactivate regulatory sequences in the
Bapx1 promoter and that they physically interact with the
Bapx1 promoter region. These results strongly suggest that
Bapx1 is a direct target of Pax1 and Pax9. Together, we
conclude that Pax1 and Pax9 are required and sufficient for
the chondrogenic differentiation of sclerotomal cells.
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Pax1 and Pax9, the ventromedial structures of the vertebral
column are not formed (Peters et al., 1999). Thus, there is a
functional redundancy between the two Pax genes during
vertebral column development. The sclerotomal cells of
embryos deficient for both Pax1 and Pax9 do not properly
condense around the notochord and cannot initiate
chondrogenesis. There is a decrease in the proliferation rate of
the sclerotomal population in Pax1;Pax9-double mutants,
followed by an increase in apoptosis (Peters et al., 1999). 
The secreted molecule Sonic hedgehog (Shh), which is
produced by the notochord and the floor plate, plays pivotal
roles in the dorsoventral patterning of somites and in the
survival of sclerotomal cells (Fan and Tessier-Lavigne, 1994;
Johnson et al., 1994; Chiang et al., 1996). Sclerotomal
expression of several genes including Pax1 and Pax9 is known
to be dependent on Shh (Brand-Saberi et al., 1993; Dietrich et
al., 1993; Koseki et al., 1993; Neubüser et al., 1995).
Bapx1 (also known as Nkx3-2) and Nkx3-1 genes are the
mouse homologs of Drosophila Nk-3/bagpipe (bap), a
mesodermal gene essential for the formation of the visceral
musculature (Azpiazu and Frasch, 1993). They are expressed
in the sclerotome (Tribioli et al., 1997; Tanaka et al., 1999; Kos
et al., 1998) in a Shh-dependent manner (Murtaugh et al., 2001;
Kos et al., 1998). Nkx3-1-deficient mice show no sclerotomal
defects (Bhatia-Gaur et al., 1999; Schneider et al., 2000).
Interestingly, mouse mutants lacking Bapx1 show a vertebral
phenotype strikingly similar to that of mice mutant for both
Pax1 and Pax9 (Lettice et al., 1999; Tribioli and Lufkin, 1999;
Akazawa et al., 2000). Overexpression experiments in the
chick have recently demonstrated the role of Bapx1 in
chondrogenic differentiation of sclerotomal cells in response
to Shh (Murtaugh et al., 2001). As neither Pax1 nor Pax9
expression is altered in Bapx1 mutants (Lettice et al., 1999;
Tribioli and Lufkin, 1999; Akazawa et al., 2000), the
possibility exists that Bapx1 might be a downstream target of
Pax1 and Pax9.
In this study, this possibility was tested by a combination
of genetic and molecular approaches. We show that Bapx1
expression in the sclerotome is dependent on the two Pax
genes. We also show that Pax1 and Pax9 are not only
necessary, but also sufficient for Bapx1 expression and for the
induction of sclerotome chondrogenesis. Furthermore, we
have obtained strong evidence that Bapx1 is a direct target of
Pax1 and Pax9 in the sclerotome. Taken together, we conclude
that Pax1 and Pax9, as main mediators of Shh signaling, are
essential and sufficient for the induction of sclerotome
chondrogenesis.
MATERIALS AND METHODS
In situ hybridization
Pax1;Pax9 mutant embryos were generated and genotyped as
previously described (Peters et al., 1999). Paraffin wax embedded
sections and whole-mount in situ hybridization was performed as
described (Neubüser et al., 1995). An Nkx3-1 probe was obtained by
RT-PCR on mouse genomic DNA with the following primers, 5′-
CACAGTGGCTGATGTCAAGG-3′ and 5′-AAGCATGAACGGAG-
AGGTCC-3′, to amplify the 3′UTR (position 793 to 1704)
(Sciavolino et al., 1997). Meox2 (Candia et al., 1992), Bapx1 (Lettice
et al., 2001) and Nkx3-1 RNA probes were labeled with digoxigenin
and developed with BM-purple (Roche). Meox1 (Candia et al., 1992)
RNA probe was labeled with fluorescein and developed with Fast
Red (Roche). No signal was obtained with sense probes in all cases
(not shown).
Retroviral vectors
pRCAS(A)-Pax1
The coding region of mouse Pax1 was excised from pPax1 (see below)
with NcoI/EcoRI and subcloned in NcoI/EcoRI-digested pSlax13
shuttle vector (a gift from C. Tabin) (Logan and Tabin, 1998) to create
pSlax-Pax1. To engineer an HA N-terminal epitope, the following two
oligonucleotides were annealed to create an HA linker with NcoI
cohesive ends: 5′-CATGTACCCATACGATGTTCCAGATTACGCT-
GG-3′ and 5′-CATGCCAGCGTAATCTGGAACATCGTATGGGTA-
3′. This HA linker was ligated to NcoI linearized pSlax-Pax1 to
generate a HA-Pax1 fragment. This fragment was excised from
pSlax13 with ClaI and subcloned into ClaI-digested pRCASBP(A)
(Hughes et al., 1987). The identity of the final product was confirmed
by sequencing. Western blot on RCAS-A-Pax1 infected chick embryo
fibroblasts (CEF) with HA11 antibody (BAbCO) against the HA
epitope confirmed expression of HA-Pax1 protein (not shown).
Immunocytochemistry analysis on RCAS-Pax1-infected CEF showed
nuclear localization of HA-Pax1 (not shown), as expected for its role
as transcription factor. The control vector pRCAS(A)-AP contains a
human placental alkaline phosphatase cDNA (a gift from C. Tabin)
(Fekete and Cepko, 1993).
Explant cultures, viral infection and RT-PCR
Fertile chicken White Leghorn eggs were obtained from Needle farm,
Hertfordshire, UK. Chick presomitic mesoderm from HH10 stage
embryos were isolated and embedded in collagen gels as described
(Münsterberg et al., 1995). We used the semi-defined serum-free
culture medium as described (Murtaugh et al., 1999) with or without
Shh (Ontogeny) supplement at 500 ng/ml. Retroviral infection was
performed as described (Maroto et al., 1997) with 4×104 cfu of
RCAS-Pax1 and 2×105 cfu of RCAS-AP. Explants were harvested on
the fifth day and processed for RT-PCR.
RT-PCR was carried out essentially as described (Münsterberg et
al., 1995), except that 10% DMSO was included in the RT reaction
mixture. Amplification of chick Bapx1 was performed in the presence
of 5% formamide at annealing temperature 65°C with primers 5′-
GCTCCCGCGCCGCCTTCTCC-3′ and 5′-GGCGGCCGCGGCA-
CAGGACAG-3′. The specificity of the amplified product was
confirmed by subcloning and sequencing. Aggrecan was amplified as
described (Murtaugh et al., 1999) at annealing temperature 50°C.
Mouse Pax1 was amplified at annealing temperature 60°C with
primers 5′-GCTGCCTACTCCCCCAAGA-3′ and 5′-CGCTGTA-
TACTCCGTGCTG-3′.
Plasmid construction for transactivation assays
Expression plasmids
pPax1 and pPax9 contain mouse Pax1- and Pax9-coding sequences,
respectively, under control of the CMV promoter cloned in pcDNA3
(Invitrogen). To generate pPax1, the coding region of mouse Pax1 was
amplified by RT-PCR from RNA isolated from E11.5 mouse embryos,
with primers 5′-CGTTCCATGGAGCAGACGTACGGC-3′ and 5′-
GTAGAATTCCTCTGAACCGGGCTGTGGCTC-3′, which contain
NcoI and EcoRI sites, respectively. The PCR product was cloned in
pCR2.1-TOPO vector. The insert was excised with EcoRI, subcloned
in EcoRI-digested pcDNA3 vector, checked for correct orientation
and sequenced. pPax9 was a generous gift from J. Gerber.
Reporter plasmids
p5.3Bp-luc, p2.8Bp-luc, p1.9Nk-luc, p0.9Bp-luc, p0.7Bp-luc and
p0.3Bp-luc contain genomic sequences of the mouse Bapx1 gene [5′
end positions at –5285, –2762, –1947, –880, –748 and –270,
respectively; and 3′ end +109 (+1 is the first nucleotide in the
I. Rodrigo and others
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published cDNA sequence with GenBank Accession Number
U87957)], cloned into pGL3-Basic vector (Promega) with the firefly
luciferase gene as reporter. To generate p5.3Bp-luc, a 7 kb Bapx1
genomic clone based on pBluescriptII SK (Lettice et al., 1999) was
partially digested with KpnI/BamHI, and the corresponding
fragment was subcloned into KpnI/BglII digested pGL3-Basic. The
3′ end of the insert in the final construct was confirmed to correspond
to position +109 by sequencing. p2.8Bp-luc was obtained by
excising KpnI/BglII fragment from p5.3Bp-luc. p1.9Bp-luc, p0.9Bp-
luc, p0.7Bp-luc and p0.3Bp-luc were generated by controlled
treatment with exonuclease III after KpnI/PmlI digestion of
p5.3Bp-luc (Erase-a-Base, Promega). To generate intron constructs
pBpIA-luc and pBpIB-luc, which contain the intron segment
in forward and reverse orientation, respectively, a 1.3 kb Bapx1
intron segment obtained as a RsrII/MluI fragment from the 7 kb
Bapx1 genome clone was subcloned into MluI digested pGL3-
Promoter vector (Promega) with the SV40 promoter to direct firefly
luciferase expression. Integrity of all plasmids was confirmed by
sequencing. pRL-SV40 vector (Promega) contains the reporter
Renilla luciferase gene upstream of SV40 early enhancer/promoter,
and was used to normalize the transfection efficiency among
different experiments.
Transient transfection assays
Mouse embryonic fibroblasts NIH3T3 or monkey kidney COS-7 cells
were plated into six-well plates in DMEM medium (GibcoBRL)
supplemented with 10% fetal calf serum (GibcoBRL). When cells
reached about 35% confluency, the DNA was transfected with
Lipofectamine Plus reagent (Invitrogen). In each experiment, 0.5 µg
of firefly reporter plasmid was co-transfected with different amounts
of pPax1, pPax9 or pcDNA3 control vector. The total amount of
transfected DNA was made equal in each experiment by completing
with pcDNA3. In addition, 20 ng of pRL-SV40 vector was always co-
transfected for normalization. Forty-two hours after transfection, at
about 100% confluence, cell extracts were collected and firefly and
Renilla luciferase activities were measured (Dual-Luciferase Reporter
Assay, Promega). Firefly luciferase activity in each sample was
normalized to Renilla luciferase to correct for variations in
transfection efficiency. For each assay, two to nine experiments were
performed in duplicate.
Sequence analysis
Mouse and human genome sequences including Bapx1 used for
comparison are taken from NW_000229 and AF009802, respectively.
Percent Identity Plot (PIP), TFSEARCH and MatInspector analyses
were carried out with programs available at the websites of The
Pennsylvania State University (http://bio.cse.psu.edu), Computational
Biology Research Center (http://www.cbrc.jp) and Genomatix
(http://www.genomatix.de), respectively.
Electrophoretic mobility shift assay (EMSA) 
Pax1, Pax9 and luciferase (control) proteins were synthesized by
TNT-coupled wheatgerm extract system (Promega). EMSA was
performed basically as previously described (Hennighausen and
Lubon, 1987). Protein translation extracts (2 µl) were incubated at
room temperature for 15 minutes with 5×104 cpm of each
corresponding 32P-labeled double stranded oligonucleotide and 1 µg
of poly(dI-dC) in 15 µl of 20 mM HEPES pH 7.9, 60 mM KCl, 10%
glycerol, 0.1 mM EDTA, 2 mM MgCl2, 1 mM dithiothreitol and 0.1%
bovine serum albumin. The reaction mixture was analyzed by
electrophoresis and visualized by autoradiography. In competition
assays, a 250 or 500-fold excess of cold double-stranded
oligonucleotide was pre-incubated at room temperature for 15 minutes
before the addition of the labeled oligonucleotide. In reactions
including antibodies, 1 µl (2 µg) of anti-Pax1 goat polyclonal
antibody (M-19, Santa Cruz Biotechnology) or 3 µl (1.2 µg) of goat
anti-mouse antibody as control (115-035-068, Jackson Immuno
Research Laboratories) was added and incubated for 20 minutes at
room temperature before the addition of the probe. The
oligonucleotides B4, B5, S4, S1 and S2 from the Bapx1 promoter
region are as shown in Fig. 7B. The Drosophila-derived
oligonucleotides e5-5 and e5-3 correspond to the oligonucleotides 5
and 3, respectively, described elsewhere (Chalepakis et al., 1991).
RESULTS
Bapx1 expression in the sclerotome requires
Pax1/Pax9
In order to identify target genes of Pax1/Pax9 in the
sclerotome, expression of potential candidates that show
overlapping expression domains with these Pax genes in
somites has been analyzed by whole-mount in situ
hybridization in mutant embryos deficient in Pax1 and Pax9.
Meox1 and Meox2 (also known as Mox1 and Mox2,
respectively) constitute a subfamily of homeobox-containing
genes that are expressed in the sclerotome (Candia et al., 1992).
Meox1 plays a critical role in axial skeleton development
(Stamataki et al., 2001), while Meox2 is dispensable for the
formation of the vertebral column (Mankoo et al., 1999). As
shown in Fig. 1, somitic expression of neither Meox1 (Fig.
1A,B) nor Meox2 (Fig. 1C,D) is altered in the absence of both
Pax1 and Pax9. In single Pax1 or Pax9 homozygous mutant
embryos, expression of Meox1 and Meox2 is also not affected
(not shown). 
We then examined expression of Nkx3-1 and Bapx1 in
Fig. 1. Expression of
sclerotomal genes in
Pax1;Pax9 mutant embryos.
Whole-mount in situ
hybridization for Meox1
(A,B; E10.5), Meox2 (C,D;
E10.5), Nkx3-1 (E,F; E9.5)
and Bapx1 (G,H; E11.5) on
wild type (w.t.; A,C,E,G) or
Pax1–/–, Pax9–/– (B,D,F,H)
mouse embryos.
476
Pax1;Pax9 mutants. Nkx3-1 expression in the sclerotome of
Pax1;Pax9-double homozygous embryos remains unchanged
(Fig. 1E,F). Normal expression pattern is observed in single
Pax1 or Pax9 mutant embryos, as well as in Pax1;Pax9 mutant
embryos with other genotype combinations (not shown).
Interestingly, Bapx1 expression in the sclerotome is
undetectable in the absence of both Pax1 and Pax9 (Fig. 1G,H),
whereas Bapx1 expression in other domains like the
mandibular region of the first branchial arch, mesenchyme of
the limb buds (see Fig. 1H) or splanchnic mesoderm (not
shown) is not affected. We did not detect Bapx1 transcripts
even in the youngest somites of the double mutants. The lack
of Bapx1 expression in the Pax1;Pax9-deficient sclerotome was
confirmed by in situ hybridization on sagittal and transverse
sections (Fig. 2). It is noteworthy that sclerotomal cells that
express Meox1, Meox2 and Nkx3-1 are present in the double
mutants. This indicates that the loss of Bapx1 expression is not
a secondary consequence of lack of sclerotomal cells, but it is
rather a very early molecular defect caused by the absence of
the sclerotomal Pax genes.
When we analyzed Pax1-single homozygous mutant
embryos, we invariably observed a decrease in the intensity of
Bapx1 staining in the sclerotome, when compared with wild-
type littermates (Fig. 3A,B,E,F). However, Bapx1 expression
in the sclerotome of Pax9-single deficient embryos did not
show significant changes (Fig. 3C,D). When only one
functional copy of Pax1 is present (Pax1+/–, Pax9–/–), the level
of Bapx1 expression is considerably reduced (compare Fig. 1G
with Fig. 1E). Bapx1 expression is even weaker, when only one
functional Pax9 gene copy is present (Pax1–/–, Pax9+/–; Fig.
1H). These results indicate that somitic Bapx1 expression is
dependent on the presence of Pax1 and Pax9 in a dose-
dependent manner, with Pax1 having a stronger role than Pax9.
In summary, these data indicate that Meox1, Meox2 and
Nkx3-1 expression in the sclerotome is not dependent on the
Pax1/Pax9 activity. They may act either upstream, or in
different regulatory pathways. However, somitic expression of
Bapx1 requires Pax1 and Pax9. 
Pax1 can substitute for Shh in the induction of
Bapx1 expression and sclerotome chondrogenesis
In order to assess the potential of Pax1 and Pax9 to activate
Bapx1, we have employed a retroviral system to overexpress
Pax1 in explants of chick presomitic mesoderm (PSM). When
the explants were grown in the absence of Shh, we did not
detect Bapx1 expression (Fig. 4A, lane 1). However, we
observed Bapx1 induction when the explants were exposed to
Shh (Fig. 4A, lane 3), as previously reported (Murtaugh et al.,
2001). Because one of the early effects of Shh is the induction
of Pax1 (Fan and Tessier-Lavigne, 1994; Johnson et al., 1994;
Münsterberg et al., 1995; Murtaugh et al., 1999), there is the
possibility that Shh acts through Pax1 to activate Bapx1
expression. Interestingly, we observed that overexpression of
mouse Pax1 in chick PSM explants cultured in medium with
Shh led to a significant increase of the Bapx1 expression levels
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Fig. 2. Absence of Bapx1 expression in the sclerotome of Pax1;Pax9-
deficient embryos. In situ hybridization for Bapx1 on sagittal (A,C)
and transverse (B,D) sections of wild type (w.t.; A,B) or Pax1–/–,
Pax9–/– (C,D) E11.5 mouse embryos at the lumbar level. The arrows
indicate the notochord (n). Note that in the mutant embryo (C,D)
loose mesenchyme of sclerotomal cells around the notochord lack
Bapx1 expression.
Fig. 3. Bapx1 expression level
depends on the Pax1/Pax9 gene
dosage. Whole-mount in situ
hybridization for Bapx1 on E9.5 (A-
D) or E10.5 (E-H) mouse embryos.
Genotypes are indicated on top of
each panel. w.t., wild type. Note the
decrease in Bapx1 staining intensity,
as fewer functional copies of Pax1 or
Pax9 are present.
477Activation of Bapx1 by Pax1 and Pax9
(Fig. 4A, lane 4, compare with lane 3), indicating that a high
dose of Pax1 can enhance the effect of Shh on the induction
of Bapx1. Furthermore, exogenous expression of Pax1 was
sufficient to induce Bapx1, even in the absence of Shh (Fig.
4A, lane 2).
To further explore the role of Pax1 in sclerotome
differentiation, we have analyzed expression of the early
chondrocyte marker aggrecan in this in vitro system. It has
previously been reported that aggrecan is induced by Shh
treatment (Murtaugh et al., 1999), or by overexpression of
Bapx1 (Murtaugh et al., 2001) in chick PSM explants.
Consistent with these published observations, as well as our
finding that Pax1 alone can induce Bapx1, we have observed
that overexpression of Pax1, in the absence of Shh, promotes
aggrecan expression (Fig. 4B, lane 2). 
Pax1 and Pax9 can transactivate Bapx1 promoter
Our data suggest that Pax1 and Pax9 may directly activate
Bapx1 expression. To test this hypothesis, we analyzed putative
Bapx1 regulatory sequences for their response to
transactivation by Pax1 and Pax9 in transient transfection
assays. The genomic structure of Bapx1, like other NK family
members, is simple, consisting of two exons and a single intron
of 1.3 kb. Thus, as first approximation we have analyzed the
intron as well as a 5.4 kb upstream segment (Fig. 5A). We first
tested if the 1.3 kb intron can act as an enhancer regulated by
Pax1/Pax9. No specific effect is observed when Pax1 and/or
Pax9 expression plasmids are co-transfected with a reporter
plasmid containing the 1.3 kb intron in forward or reverse
orientation upstream of the SV40 promoter (constructs pBpIA-
luc and pBpIB-luc, see Materials and Methods), in NIH3T3
and COS7 (data not shown).
We next tested the 5′ region of Bapx1 with the plasmid
p5.3Bp-luc that contains the 5.4 kb fragment, including a part
of 5′UTR and the putative promoter region of Bapx1 (positions
–5285 to +109, with position +1 being the published 5′ end of
Bapx1 exon 1) (Fig. 5A). This fragment possesses a basal
promoter activity, as it can drive luciferase expression in
NIH3T3 cells (22% of SV40 promoter activity, data not
shown). Interestingly, when p5.3Bp-luc is co-transfected with
the Pax1-expression plasmid, there is a dose-dependent
increase in the promoter activity, from 2.9 times induction (0.5
µg of the Pax1-expression plasmid) to 3.8 times induction (1.5
µg) (Fig. 5B). Co-transfection with the Pax9 expression
plasmid also induces a significant increase in the Bapx1
promoter activity up to 3.9 times (Fig. 5B). The maximum
transactivation effect is reached when both Pax1 and Pax9
plasmids are co-transfected. This transactivation effect is
specific for the 5.4 kb fragment, as neither Pax1 nor Pax9, or
both in combination, can activate the control vector pGL3-
Basic (see Fig. 6B and data not shown). Similar transactivation
properties are also observed in COS7 cells (not shown).
To further narrow down the region(s) responsible for the
transactivation activity of Pax1/Pax9, we generated a series of
5′ deletion constructs, as schematized in Fig. 6A, and analyzed
their response to transactivation by Pax1 and/or Pax9. Co-
transfection of p2.8Bp-luc (–2762 to +109) with the Pax1
and/or Pax9 expression plasmids leads to a significant increase
in the promoter activity of up to about eight times, when both
expression plasmids are co-transfected (Fig. 6B). Similar
Fig. 4. Pax1 induces Bapx1 expression and chondrogenesis in
explants of chick PSM. Explants of PSM isolated from stage HH10
chick embryos were infected with the control RCAS-A-AP retrovirus
(AP; A, lanes 1,3; B, lane 1) or with the RCAS-A-Pax1 retrovirus
overexpressing mouse Pax1 (A, lanes 2,4; B, lane 2), and cultured in
the absence (A, lanes 1,2; B) or the presence (A, lanes 3,4) of 500
ng/ml Shh. After 5 days of culture, explants were harvested and
analyzed by RT-PCR. The PCR products for chick Bapx1, aggrecan,
Gapdh and mouse Pax1 are shown.
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Fig. 5. Pax1 and Pax9 can transactivate Bapx1 promoter. (A) Scheme
of the Bapx1 genomic structure and of the p5.3Bp-luc reporter
plasmid. The boxes indicate exons of Bapx1 (top) or the luciferase
(luc) reporter (bottom). The coding regions of Bapx1 are shown by
the black boxes, together with the first ATG codon (position +277)
and the stop codon (TGA) in exon 2. The p5.3Bp-luc plasmid
contains 5.4-kb genomic sequences from the Bapx1 promoter region
and a part of 5′ UTR (–5285/+109) upstream of the luciferase
reporter. (B) Promoter activities of the p5.3Bp-luc construct alone or
co-transfected with the indicated amounts of expression plasmids for
Pax1 (pPax1) or Pax9 (pPax9), or both. Numbers inside or above the
bars indicate time fold induction with respect to the basal p5.3Bp-luc
promoter activity. Lines in the bars indicate s.d.
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activities are observed for p1.9Bp-luc (–1947 to +109) and
p0.9Bp-luc (–880 to +109) (Fig. 6B). Interestingly, when
additional 5′ 132-bp sequences in p0.9Bp-luc are deleted
(p0.7Bp-luc; –748 to +109), the activation properties of
Pax1/Pax9 significantly drops by more than half, but still with
3.0- to 3.4-fold transactivation capacity. The shortest segment
tested in p0.3Bp-luc (–270 to +109) is similarly activated by
Pax1/Pax9 (Fig. 6B). These data indicate that the region
between –880 and +109 contains cis-regulatory elements
responsible for Pax1/Pax9-induced transactivation.
Comparative sequence analysis of the Bapx1
promoter region
Sequence comparison between 8550 bp mouse and 8600 bp
human genomic regions encompassing the Bapx1 gene shows
a significant degree of similarities even outside the coding
sequences (Fig. 7A). In the region between –880 and +109,
overall sequence conservation is as high as 72% between the
two species. Most of conserved noncoding sequences (CNS)
as revealed by PIP analysis (Schwartz et al., 2000) are located
in this interval (Fig. 7A). Two prominent CNS segments are
found in the regions between –543 and –408 (136 nucleotides,
78%) and between +92 and +198 (107 nucleotides, 82%). The
interval between –880 and –748 (boxed in green in Fig. 7A,
and marked in green in Fig. 7B), which is important for
Pax1/Pax9-responsiveness, also includes two short CNS
segments (69 nucleotides, 80% and 69 nucleotides, 78%) that
are separated by a single-base gap. These data suggest that
most of important cis-regulatory elements of Bapx1 reside in
the region between –880 and +109.
Pax1 and Pax9 directly interact with Bapx1 promoter
sequences
In order to ascertain whether Pax1 and Pax9 directly activate
Bapx1 via binding to its cis-regulatory sequences, we
performed electrophoretic mobility shift assays (EMSA) with
in vitro translated Pax1 and Pax9 proteins and a series of
labeled oligonucleotides from the region between –880 and
–748. When EMSA was performed with the labeled
oligonucleotides B5 or S4 (Fig. 7B) and Pax1 protein, we did
not detect any retarded band (not shown). Interestingly, when
we incubated the labeled oligonucleotide B4 (Fig. 7B) with
Pax1 protein, we detected two retarded protein-DNA
complexes (Fig. 7C, lane 1). These bands represent the
complex of Pax1 protein with B4, as they did not appear when
an in vitro synthesized control protein was employed (Fig. 7C,
lane 6), and as they were specifically competed by an excess
of the cold e5-5 oligonucleotide that has previously been
shown to bind Pax1 (Fig. 7C, lanes 2, 3); but not by e5-3, a
mutated sequence that does not bind Pax1 (Fig. 7C, lanes 4,
5). The lower band could be due to partial Pax1 synthesis or
to a Pax1 degradation product. The binding of the larger form
of Pax1 to B4 was specifically blocked when an anti-Pax1
antibody was included in the binding reaction (Fig. 7D, lane
4), confirming that the bound protein is Pax1.
By competition experiments with the oligonucleotides S1
and S2, located in the 5′ or 3′ part of B4, respectively (see Fig.
7B), we could narrow down the binding region of Pax1 to
positions –880 to –844, as an excess of the cold S1 specifically
competed Pax1 binding to B4, whereas S2 did not (Fig. 7E,
lanes 4, 5 and lanes 6, 7). Furthermore, by labeling S1 and S2,
we confirmed that Pax1 binds to S1, but not to S2 (Fig. 7F,
lanes 2, 5). Similarly, we did not detect any retarded band when
we incubated Pax9 protein with the labeled B5, S4 and S2
oligonucleotides (Fig. 7F, lane 6, and data not shown), but we
detected a weak, but specific, band when Pax9 was incubated
with B4 and S1 (Fig. 7F, lane 3, and data not shown). 
DISCUSSION
Previous studies have shown that Bapx1 mediates Shh
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Fig. 6. Pax1 and Pax9
transactivation activity on
different Bapx1 promoter
deletion constructs. (A) Bapx1
promoter deletion plasmids
used in transient transfection
assays. (B) Luciferase activity
driven by the Bapx1 promoter
deletion constructs or control
vector (pGL3-Basic), alone or
co-transfected with the
indicated amounts of
expression plasmids for Pax1
(pPax1) or Pax9 (pPax9), or
both. Numbers inside or above
the bars indicate the time fold
induction with respect to the
basal activity of the same
construct in the absence of
transfected Pax1 and Pax9.
Lines in the bars indicate s.d.
479Activation of Bapx1 by Pax1 and Pax9
signaling to induce chondrogenic differentiation in the
sclerotome. However, how the Shh signal leads to Bapx1
activation remains unclear. In the present study, we have
provided evidence that Pax1 and Pax9 are not only required,
but also sufficient to induce Bapx1 expression and sclerotome
chondrogenesis. This indicates that Shh signaling indirectly
activates Bapx1 via Pax1 and Pax9. Furthermore, our results
have shown that Pax1 and Pax9 can transactivate the Bapx1
promoter and that both Pax proteins can bind in vitro to a
specific region of the promoter, strongly suggesting that Bapx1
is a direct target of the two Pax genes. Striking similarity in
the axial skeleton defects between Bapx1- and Pax1;Pax9-
deficient mice strongly suggests that Bapx1 is a main
downstream effector of Pax1 and Pax9. Therefore, in order to
understand the mechanisms involved in sclerotome
chondrogenesis at the molecular and cellular levels, it will be
important to identify targets of Bapx1 in the sclerotome.
Despite the similarity in the expression patterns between
Pax1/Pax9 and Bapx1 in the early phase of sclerotome
development, their expression profiles significantly differ at the
Fig. 7. Pax1 and Pax9 bind to
regulatory sequences of the
Bapx1 promoter. (A) PIP analysis
of an 8550 bp mouse Bapx1
genome sequence when
compared with an 8600 bp
human BAPX1 sequence. Exons
are outlined in black and coding
parts are gray. Numbers at the top
indicate nucleotide positions as
defined in the text, and they
correspond to 5′ ends of intervals
included in the series of deletion
constructs used in the
transactivation assay. The interval
between –880 and –748 is
outlined in green. PIP scores in
% are shown on the right, with
50% identity at the bottom level.
Note the presence of several CNS
segments outside the coding
region. Many of them are located
in the interval between –880 and
+109. (B) Sequence of the
interval between –880 and –731.
The different oligonucleotides
(S1, S2, B4, B5 and S4)
employed in EMSA assays are
indicated by lines. Sequence in
green (–880 to –748) corresponds
to the segment included in the
plasmid p0.9Bp-luc, but not in
the plasmid p0.7Bp-luc. A
potential Pax6-binding site
predicted by TFSEARCH and
MatInspector is in the region of
S1 and indicated in red.
(C-F) Results of EMSA
experiments. The indicated
labeled oligonucleotides (Probe,
marked with an asterisk) were
incubated with the in vitro
translated protein (Prot.) Pax1,
Pax9 or luciferase as a control
(C), separated and visualized as
described in the Materials and Methods. The specific Pax1 (black arrows) and Pax9 (gray arrow in F) complexes are indicated. (C) Pax1 binds
to oligonucleotide B4. Cold oligonucleotides e5-5 or e5-3 were added at 250-fold (lanes 2, 4) or 500-fold (lanes 3, 5) molar excess, as
indicated. e5-5 specifically competes with B4 for Pax1 binding, whereas mutated e5-3 does not. (D) Specific inhibition of Pax1-B4 complex
formation by anti-Pax1 antibody. The indicated antibodies were incubated in the binding reactions. αP1, anti-Pax1 goat antibody; αC, anti-
mouse goat antibody, used as control. The anti-Pax1 antibody abrogates the formation of the larger complex. (E) Competition experiments
employing a 250-fold (lanes 2, 4, 6) or 500-fold (lanes 3, 5, 7) molar excess of cold oligonucleotides B4, S1 or S2. Note that oligonucleotides
B4 and S1 compete with B4 for Pax1 binding, whereas oligonucleotide S2 does not. (F) Binding of Pax1 and Pax9 to oligonucleotide S1. S1 or
S2 labeled oligonucleotides were incubated with Pax1, Pax9 or luciferase control protein as indicated. Both Pax1 and Pax9 interact with S1
oligonucleotide, but not with S2 oligonucleotide.
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later stages. Once chondrogenesis has started, both Pax1 and
Pax9 are rapidly downregulated, while Bapx1 expression is
maintained in chondrocytes even after Pax1/Pax9 expression
diminishes (Tribioli et al., 1997; Murtaugh et al., 2001). This
observation suggests that Pax1/Pax9 may be required only for
the initiation of Bapx1 expression, but not for its maintenance.
Accordingly, it has recently been proposed that an auto-
regulatory loop between Bapx1 and Sox9 maintains expression
of both in sclerotome derivatives (Zeng et al., 2002). As
expression of Sox9 is initiated in young somites of Pax1;Pax9-
deficient embryos (Peters et al., 1999), induction of Sox9
expression in sclerotome cells does not appear to be dependent
on Pax1 and Pax9, and probably not on Bapx1. How
sclerotomal Sox9 expression is initiated remains to be
elucidated. 
A conserved regulatory pathway
The Drosophila homolog of Bapx1, bagpipe (bap), is
expressed in a subset of dorsal mesodermal cells and in the
absence of the bap function, the development of the visceral
musculature is disrupted (Azpiazu and Frasch, 1993). As
Bapx1 mutant mice show no defects in the formation of the gut
musculature, it has been proposed that there is no equivalent
function for the mouse and Drosophila genes (Lettice et al.,
1999). Nevertheless, there could be still common regulatory
mechanisms. In Drosophila embryos, the dorsal mesoderm
homeobox gene tinman (tin), in combination with
decapentaplegic (dpp), activates bap expression (Azpiazu and
Frasch, 1993; Staehling-Hampton et al., 1994). The zinc-finger
transcription factor schnurri (shn) has been proposed to
mediate dpp-mediated bap activation (Staehling-Hampton et
al., 1995). In addition, the ectodermal segmental regulators
hedgehog (hh), wingless (wg) and sloppy paired (slp) restrict
bap to segmental clusters of cells within the dorsal mesoderm,
with hh having a positive and wg and slp a negative effect on
bap regulation (Azpiazu et al., 1996; Riechmann et al., 1997;
Lee and Frasch, 2000). However, wg and hh signals are not
sufficient to mediate normal mesoderm segmentation and bap
activation (Azpiazu et al., 1996). It is postulated that as yet
unidentified genes, expressed in stripped pattern in the early
mesoderm, are responsible for early bap segmental expression,
and that pox meso (poxm) might fulfill those conditions
(Azpiazu et al., 1996). poxm is the Drosophila paired gene that
is most related to Pax1/Pax9, as it is expressed in
mesoderm and lacks a homeodomain (Bopp et al., 1989).
Thus, the regulatory pathway involving positive regulation
of Bapx1 by Pax1/Pax9 in mesodermal tissues could be
conserved through evolution.
Pax1 and Pax9 in sclerotome chondrogenesis
It is proposed that Shh alters the competence of somitic
cells to activate the chondrogenic differentiation program
in response to subsequent BMP signals, and that Shh
induces the expression of still unknown chondrogenic
‘competence factors’ (Murtaugh et al., 1999). Recently, it
has been shown that Bapx1 is one of such competence
factors, as it is induced by Shh, and that overexpression of
Bapx1 in chick PSM mimics the chondrogenic effects of
Shh (Murtaugh et al., 2001). Misexpression of Bapx1 in
vivo through retroviral infection in the chick embryo leads
to an expansion of the axial skeleton with thickened and
often fused neural arches, and an ectopic eighth ‘riblet’
(Murtaugh et al., 2001). In the present study, we show that Pax1
also possesses chondrogenic properties, as it can induce
aggrecan expression in cultures of chick PSM (Fig. 4B).
Therefore, Pax1 can also be regarded as one of the competence
factors. 
We also tried to overexpress Pax9 in chick PSM using a
retroviral construct RCAS(B) (Hughes et al., 1987) engineered
to express mouse Pax9 (RCAS-B-Pax9). We observed neither
Bapx1 nor aggrecan upregulation when chick PSM explants
were exposed to RCAS-B-Pax9 viral supernatant. The lack of
positive results with the Pax9 retroviral system could be due to
technical problems, such as the low viral titer obtained (<107
cfu/ml), or the use of a different viral vector (RCAS-B) that
might infect sclerotomal cells with lower efficiency. We have
occasionally observed that injection of RCAS-B-Pax9 viral
supernatant in ovo into the PSM of the chick embryo induces
fusion of the proximal part of the ribs, thickening of the neural
arches and an ectopic eighth rib (I. R., A. M. and K. I.,
unpublished). This phenotype is strikingly similar to the one
observed by overexpressing Bapx1 (Murtaugh et al., 2001).
Therefore, together with the observed synergistic function
between Pax1 and Pax9 in sclerotome development in the
mouse and the capacity of Pax9 to transactivate the Bapx1
promoter, it is conceivable that Pax9 also can activate Bapx1
and initiate chondrogenesis in vivo.
Activation of Bapx1 expression by Pax1 and Pax9
The results from our transactivation study and EMSA assay
strongly suggest that Pax1 and Pax9 directly activate Bapx1.
From the transient transfection experiments, we assumed that
there are at least two regions responsible for positive regulation
by Pax1 and Pax9 in the Bapx1 promoter region (Fig. 6): the
intervals from –880 to –748 and from –270 to +109. We have
found that Pax1/Pax9 directly bind to a motif located in the
segment between –880 and –844 (Fig. 7). Our analysis failed
to find Pax1/Pax9-binding sequences in the interval between
–270 and +109. It is notable that transactivation by Pax1 and
Pax9 significantly enhanced when the interval between –5285
and –2762 was removed (compare p5.3Bp-luc with p2.8Bp-luc
in Fig. 6B). This observation suggests the presence of
cis-elements that negatively influence on the Pax1/Pax9
transactivation.
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Fig. 8. Model for regulatory pathways involved in sclerotome
differentiation. Ovals indicate genes with a proposed role in axial skeletal
development. See text for details.
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Pax proteins bind to specific DNA sequences through the
128 amino acid long paired domain. The paired domains in
Pax1 and Pax9 are almost identical (98%), suggesting that they
could bind the same DNA sequences. Indeed, DNA-binding
studies have shown that Pax1 and Pax9 can bind the modified
e5 motif derived from the paired binding sequence in the
Drosophila even-skipped promoter (Chalepakis et al., 1991;
Neubüser et al., 1995). Pax1 also binds in vitro with high
affinity to CD19-2 (A-ins) and H2A-17C, two modified
sequences identified originally as recognition sites for Pax5
(Adams et al., 1992; Czerny et al., 1993). Similarly, the paired
box of zebrafish Pax9 recognizes in vitro with high affinity the
original CD19-1 and modified CD19-2 (A-ins) sequences as
well as a modified sequence of e5 (Nornes et al., 1996).
However, most of these motifs are artificial consensus binding
sequences, and none of the genes from which these motifs
originate is related to normal expression or function of Pax1 or
Pax9. It has been reported that Pax1 can transactivate PDGFRα
promoter in transient transfection experiments in some cell
lines, but the maximum effect was observed with a mutated
Pax1 protein, and the effects were dependent on the cellular
context (Joosten et al., 1998). Therefore, Bapx1 may be the first
example of direct targets of Pax1 and Pax9 with a physiological
relevance. Furthermore, the sequences contained in the
oligonucleotide S1 can be considered as a novel DNA motif
for binding of Pax1 and Pax9. In silico analysis by
TFSEARCH (Heinemeyer et al., 1998) and MatInspector
(Quandt et al., 1995) predicts a potential Pax6 binding site
within the S1 region (positions –873 to –853, nucleotides
marked in red in Fig. 7B). This site might turn out to be a
Pax1/Pax9-binding site. Future study will define the nucleotide
motif in the S1 region that is specifically bound by Pax1 and
Pax9. 
Pax1/Pax9 as main mediators of Shh signaling in
sclerotome differentiation
Sclerotome differentiation is controlled by a number of
molecules and signaling pathways, the hierarchy of which we
are beginning to understand. Based on the data from published
studies, together with the evidence reported here, we propose
a model for sclerotome differentiation as schematized in Fig.
8. Paraxial mesoderm cells experience sequential changes in
their responsiveness to specific signals, as they progress
through developmental stages in the PSM, in the nascent
somites and in the sclerotome. During the transition from PSM
to somites (somite formation), paraxial mesoderm cells
become competent to respond to Shh. It is proposed that Wnt
signaling plays a key role in the establishment of this
competence, via differential regulation on Gli genes in paraxial
mesoderm cells (Borycki et al., 2000). After somites are
formed, Shh plays an essential role in the induction,
differentiation and survival of sclerotomal cells, by activating
several transcription factors, including Pax1, Pax9, Nkx3-1 and
Bapx1 (thin arrows in Fig. 8). Once sclerotomal cells are
specified, some of these transcription factors (circled in Fig. 8;
i.e. Meox1, Pax1 and Pax9) play a role in further sclerotome
differentiation and in chondrogenesis (green arrows in Fig. 8),
by activating their downstream targets, including Bapx1.
Although Nkx3-1 and Meox2 are shown to be dispensable for
proper axial skeleton formation, their potential roles in the
sclerotome still cannot be ruled out. They might have a
functional redundancy with their closely related genes Bapx1
and Meox1, respectively. Therefore, whether mice double
mutant in Nkx3-1;Bapx1 or in Meox1;Meox2 show synergistic
defects is of great interest. Finally, whether the Shh signaling
pathway directly activates Pax1 and Pax9 is also not known.
Shh signaling might indirectly activate Pax1 and Pax9, by
activating other transcription factors like Meox1 and Meox2.
Analysis of Pax1 and Pax9 expression in mice deficient in both
Meox1 and Meox2 will clarify this point. 
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